Edesa Biotech, Inc.

EDSA

NASDAQHealthcareBiotechnology

在 GoAI 中打開

GoAI 研究快照

簡明呈現最新可用的模型資訊。

2026年7月10日

36/ 100

GoAI評分

Sell

Trim exposure — unfavorable risk-reward

估值

Expensive

動能

Neutral

情緒

Bullish

風險韌性

High Risk

完整 GoAI 研究

繼續查看更深入的依據、催化因素和風險。

看完整研究

人工智慧產生的上下文僅供參考，並非投資建議。

公司概況

公司網站

Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.

產業: Biotechnology
部門: Healthcare
總部: CA
執行長: Pardeep Nijhawan
上市以來: 2010年6月21日
僱員: 17